LLNI announces funding for MOSAICC Study

The MOSAICC study: Piecing together the causes of myeloproliferative neoplasms 

Leukaemia & Lymphoma NI were delighted to announce that they will br providing £47,000 of funding to the MOSAICC Study.

Researchers at Queen’s University Belfast and the University of Aberdeen are leading the largest ever case-control study of myeloproliferative neoplasms (MPNs), a group of rare blood cancers, who often experience symptoms such as debilitating fatigue, reduced quality of life (QoL) and capacity to complete routine daily activities.  The causes of MPNs remain unknown.

The MOSAICC (MyelOproliferative neoplasmS: An In-depth Case Control) study builds on a successful pilot study led by researchers at Queen’s University Belfast, aiming to identify potential causes of MPNs; assess symptom burden and QoL and collect DNA, RNA and toenail samples for future studies of gene/environment interactions. 

The study team aim to recruit at least 560 patients with MPNs across 18 sites in the UK as well as a similar number of non-blood relatives/friends controls.  Cases and controls who agree to participate will be invited to take part in a telephone-based interview regarding their lifestyle, medical and occupational history.  Participants will also be asked to give details of their job and residential history, complete QoL questionnaires and provide blood and saliva samples and toe-nail clippings. 

This study will provide much needed information on risk factors for MPNs and the impact that this condition has on patients QoL.

The MOSAICC study is funded by Leukaemia and Lymphoma NI (LLNI) and MPN Voice.